These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33173569)
1. Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Ullah W; Mukhtar M; Al-Mukhtar A; Saeed R; Boigon M; Haas D; Rame E World J Cardiol; 2020 Oct; 12(10):501-512. PubMed ID: 33173569 [TBL] [Abstract][Full Text] [Related]
2. Soluble guanylate cyclase stimulators for heart failure: a network meta-analysis and subgroup analyses of reduced and preserved ejection fraction. Abuelazm MT; Attia A; Abdelnabi M; Jafar U; Almaadawy O; Elzeftawy MA; Mahmoud A; Albakri K; Abdelazeem B Egypt Heart J; 2024 Jan; 76(1):6. PubMed ID: 38265696 [TBL] [Abstract][Full Text] [Related]
3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Li Q; Li Z; Li T; Wang Y; Feng J; Lu C Pharmazie; 2021 Oct; 76(10):488-493. PubMed ID: 34620276 [No Abstract] [Full Text] [Related]
5. Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. Moghaddam N; Malhi N; Toma M Am Heart J; 2021 Nov; 241():74-82. PubMed ID: 34283990 [TBL] [Abstract][Full Text] [Related]
6. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction. Kang C; Lamb YN Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347 [TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Pieske B; Butler J; Filippatos G; Lam C; Maggioni AP; Ponikowski P; Shah S; Solomon S; Kraigher-Krainer E; Samano ET; Scalise AV; Müller K; Roessig L; Gheorghiade M; Eur J Heart Fail; 2014 Sep; 16(9):1026-38. PubMed ID: 25056511 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Zheng X; Zheng W; Xiong B; Huang J Medicine (Baltimore); 2018 Oct; 97(41):e12709. PubMed ID: 30313068 [TBL] [Abstract][Full Text] [Related]
9. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. Breitenstein S; Roessig L; Sandner P; Lewis KS Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610 [TBL] [Abstract][Full Text] [Related]
10. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. Coats AJS; Tolppanen H Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114 [TBL] [Abstract][Full Text] [Related]
11. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Aimo A; Castiglione V; Vergaro G; Panichella G; Senni M; Lombardi CM; Emdin M Heart Fail Rev; 2022 Jul; 27(4):1165-1171. PubMed ID: 34291399 [TBL] [Abstract][Full Text] [Related]
12. Vericiguat for Heart Failure with Reduced Ejection Fraction. Lombardi CM; Cimino G; Pagnesi M; Dell'Aquila A; Tomasoni D; Ravera A; Inciardi R; Carubelli V; Vizzardi E; Nodari S; Emdin M; Aimo A Curr Cardiol Rep; 2021 Aug; 23(10):144. PubMed ID: 34410527 [TBL] [Abstract][Full Text] [Related]
13. Emerging concepts in heart failure management and treatment: focus on vericiguat. Kaplinsky E; Perrone S; Barbagelata A Drugs Context; 2023; 12():. PubMed ID: 36660012 [TBL] [Abstract][Full Text] [Related]